Table of Content

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
What’s New in This Report?
Scope of Report
Research Methodology
Information Sources
Geographic Breakdown

Chapter 2 Summary and Highlights
Market Outlook
Market Summary

Chapter 3 Market Overview
Overview of Cardiovascular Disease
Coronary Artery Disease
Atherosclerosis
Angina (Angina Pectoris)
Acute Myocardial Infarction
Medical Management
Lifestyle Changes
Diet Modification
Smoking Cessation
Pharmaceuticals
Anticoagulants and Antiplatelet Drugs
Major Drivers
Coagulation Factors Targeted to Reduce CVD
The Global Burden of Cardiovascular Disease
2030 Global Burden of Cardiovascular Disease
The Global Economic Burden of Cardiovascular Disease
Sales Performance of Major Drugs in 2022

Chapter 4 Global Market for Anticoagulant Drugs
Overview
Products
Low Molecular Weight Heparin
Oral Anticoagulants (Vitamin K Antagonists)
Global Anticoagulant Drugs Market Forecast

Chapter 5 Global Market for Antiplatelet Drugs
Overview
Products
Oral Antiplatelets
Global Antiplatelet Drugs Market Forecast

Chapter 6 Global Market for Thrombin Inhibitors
Overview
Products
Direct Thrombin Inhibitors
Thrombolytic Agents
Direct Factor Xa Inhibitors
Global Thrombin Inhibitors Market Forecast

Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region
Overview
North America
Europe
Asia-Pacific
Rest of the World

Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
Introduction to ESG
Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
Key ESG Issues
Consumer Attitudes Towards ESG
Industry ESG Performance Analysis
Case Study

Chapter 9 Clinical Trials and Patent Landscape
Clinical Trials Analysis
Patent Analysis
Patent by Assignee

Chapter 10 M&A and Venture Funding Outlook
M&A Analysis

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL MYERS SQUIBB
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
MERCK & CO. INC.
PFIZER INC.
SANOFI

Chapter 13 Appendix
Government Regulatory Agencies and Professional Organizations



List of Figures


Summary Figure : Global Market for Antithrombotic/Anticoagulant Drugs, by Product Segment, 2020-2028
Figure 1 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age Group, 2019
Figure 2 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, 2019
Figure 3 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2019
Figure 4 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, 2019
Figure 5 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age Group, 2030
Figure 6 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, 2030
Figure 7 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2030
Figure 8 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, 2030
Figure 9 : Projected Total Costs of Cardiovascular Disease in the United States, 2015-2030
Figure 10 : Global Market for Antithrombotic/Anticoagulant Drugs, by Region
Figure 11 : Global Market Shares of Antithrombotic/Anticoagulant Drugs, by Region, 2022
Figure 12 : How a Strong ESG Proposition Benefits Businesses
Figure 13 : Global ESG-Adoption Level Across All the Industries, 2021 and 2022
Figure 14 : The Ten Business Sustainability Trends Identified for 2022
Figure 15 : Pfizer Inc.’s Most Material ESG Issues, 2020
Figure 16 : Global Market Shares of Antithrombotic/Anticoagulant Drugs, by Company, 2022
Figure 17 : Global Market Shares of Thrombin Inhibitors Drugs, by Company, 2022
Figure 18 : Global Market Shares of Anticoagulant Drugs, by Company, 2022
Figure 19 : Global Market Shares of Antiplatelet Drugs, by Company, 2022
Figure 20 : Boehringer Ingelheim: Annual Revenue, 2021 and 2022
Figure 21 : Boehringer Ingelheim: Revenue Share, by Business Segment, 2021 and 2022
Figure 22 : Boehringer Ingelheim: Revenue Share, by Region, 2021 and 2022
Figure 23 : Bristol-Myers Squibb: Revenue Share, by Region/Country, 2022
Figure 24 : Daiichi Sankyo: Market Share, by Region/Country, 2022
Figure 25 : Roche: Annual Revenue, 2021 and 2022
Figure 26 : Roche: Market Share, by Business Segment, 2022
Figure 27 : Roche: Revenue Share, by Business Segment, 2021
Figure 28 : Roche: Revenue Share, by Region/Country, 2021
Figure 29 : Johnson & Johnson: Financials, 2017-2021
Figure 30 : Johnson & Johnson: Revenue Share, by Region/Country, 2021
Figure 31 : Johnson & Johnson: Revenue Share, by Business Segment, 2021
Figure 32 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2022
Figure 33 : Merck & Co. Inc.: Revenue Share, by Region, 2022
Figure 34 : Pfizer Inc.: Revenue Share, by Region, 2021
Figure 35 : Pfizer Inc.: Revenue Share, by Business Segment, 2021
Figure 36 : Sanofi: Net Sales Share, by Business Segment, 2022
Figure 37 : Sanofi: Net Sales Share, by Region/Country, 2022

List of Tables

Summary Table : Global Market for Antithrombotic/Anticoagulant Drugs, by Product Segment, Through 2028
Table 1 : Standard Angina Pectoris Classification
Table 2 : Top 20 Leading Causes of Death, 2019
Table 3 : Estimated Deaths Due to Noncommunicable Diseases, by Sex and Disease, 2019
Table 4 : Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2019
Table 5 : Global Health Estimates, by Sex and WHO Region, 2019
Table 6 : Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2030
Table 7 : Estimated Deaths Due to Cardiovascular Disease, by Sex and WHO Region, 2030
Table 8 : Economic Burden of NCDs in India, 2012-2030
Table 9 : Praxbind (Idarucizumab) Drug Label
Table 10 : Global Market for Thrombin Inhibitors Drugs, by Type, 2022
Table 11 : Global Market for Anticoagulant Drugs, by Type, 2022
Table 12 : Global Market for Antiplatelet Drugs, by Type, 2022
Table 13 : Lovenox Drug Label
Table 14 : Fragmin Drug Label
Table 15 : Innohep Drug Label
Table 16 : Global Market for Anticoagulant Drugs, by Region, Through 2028
Table 17 : Global Market for Anticoagulant Drugs, by Type, Through 2028
Table 18 : Global Market for Low Molecular Weight Heparin Anticoagulant Drugs, by Region, Through 2028
Table 19 : Global Market for Oral Anticoagulant Drugs, by Region, Through 2028
Table 20 : Plavix Drug Label
Table 21 : Pletal Drug Label
Table 22 : Effient Drug Label
Table 23 : Global Market for Antiplatelets, by Type, Through 2028
Table 24 : Global Market for Antiplatelets, by Region, Through 2028
Table 25 : Global Market for Oral Antiplatelets, by Region, Through 2028
Table 26 : Global IV Market for Antiplatelets, by Region, Through 2028
Table 27 : Global Market for Thrombin Inhibitors, by Type, Through 2028
Table 28 : Global Market for Thrombin Inhibitors, by Region, Through 2028
Table 29 : Global Market for Direct Factor Xa Inhibitors, by Region, Through 2028
Table 30 : Global Market for Direct Thrombin Inhibitors, by Region, Through 2028
Table 31 : Global Market for Direct Thrombolytic Agents, by Region, Through 2028
Table 32 : Global Market for Antithrombotic/Anticoagulant Drugs, by Region, Through 2028
Table 33 : North American Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
Table 34 : North American Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 35 : North American Market for Anticoagulant Drugs, by Type, Through 2028
Table 36 : North American Market for Antiplatelets, by Type, Through 2028
Table 37 : North American Market for Thrombin Inhibitors, by Type, Through 2028
Table 38 : European Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
Table 39 : European Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 40 : European Market for Anticoagulant Drugs, by Type, Through 2028
Table 41 : European Market for Antiplatelets, by Type, Through 2028
Table 42 : European Market for Thrombin Inhibitors, by Type, Through 2028
Table 43 : Asia-Pacific Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
Table 44 : Asia-Pacific Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 45 : Asia-Pacific Market for Anticoagulant Drugs, by Type, Through 2028
Table 46 : Asia-Pacific Market for Antiplatelets, by Type, Through 2028
Table 47 : Asia-Pacific Market for Thrombin Inhibitors, by Type, Through 2028
Table 48 : Rest of the World Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 49 : Rest of the World Market for Anticoagulant Drugs, by Type, Through 2028
Table 50 : Rest of the World Market for Antiplatelets, by Type, Through 2028
Table 51 : Rest of the World Thrombin Inhibitors Drugs Market, by Type, Through 2028
Table 52 : Key Focus Areas in ESG Metrics: Market for Antithrombotic/Anticoagulant Drugs
Table 53 : Typical ESG Factors in Pharmaceuticals
Table 54 : Net-Zero GHG Commitments by Major Antithrombotic/Anticoagulant Drug Manufacturing Companies
Table 55 : ESG Rankings for Major Antithrombotic/Anticoagulant Drug Manufacturing Companies, 2023*
Table 56 : CDP Scope Card for Major Antithrombotic/Anticoagulant Drug Manufacturing Companies, 2022
Table 57 : Selected Thrombin Drugs in Clinical Trials, as of 2023
Table 58 : Selected Granted Thrombosis Treatment Drugs in Clinical Trials, as of 2023
Table 59 : Patents Issued on Anticoagulant Drugs, by Assignee Company, 2018-2022
Table 60 : Patents Issued on Thrombin Inhibitor Drugs, by Assignee Company, 2018-2022
Table 61 : Patents Issued on Antiplatelet Drugs, by Assignee Company, 2018-2022
Table 62 : Global Market for Antithrombotic/Anticoagulant Drugs’ Recent Mergers and Acquisitions
Table 63 : Global Market for Antithrombotic/Anticoagulant Drugs Revenue Analysis, 2022
Table 64 : Global Market for Antithrombotic/Anticoagulant Drugs Key Product Portfolio, 2022
Table 65 : Global Thrombin Inhibitors Drugs Market Revenue Analysis, 2022
Table 66 : Global Anticoagulants Drug Market Revenue Analysis, 2022
Table 67 : Global Antiplatelet Drugs Market Revenue Analysis, 2022
Table 68 : Bayer AG: Marketed Products
Table 69 : Bayer AG: Key Financials, 2021 and 2022
Table 70 : Bayer AG: Key Developments, 2022 and 2023
Table 71 : Boehringer Ingelheim: Selected Key Developments, 2019-2021
Table 72 : Bristol-Myers Squibb: Key Developments, 2020 and 2021
Table 73 : Daiichi Sankyo: Product Information
Table 74 : Daiichi Sankyo: Annual Revenue, 2020-2022
Table 75 : Daiichi Sankyo: Key Developments, 2018-2023
Table 76 : Roche: Financials, 2021 and 2022
Table 77 : Roche: Revenues, by Business Segment, 2016-2021
Table 78 : Roche: Product Portfolio
Table 79 : Roche: Diagnostics Patient Monitoring Product Portfolio
Table 80 : Roche: Recent Developments, 2019-2022
Table 81 : Johnson & Johnson: Products Portfolio for Antithrombotic/Anticoagulant Drugs Treatment
Table 82 : Johnson & Johnson: Financials, 2021
Table 83 : Johnson & Johnson: Product Portfolio
Table 84 : Johnson & Johnson: Recent Developments and Strategies, 2017-2022
Table 85 : Merck & Co. Inc.: Products Portfolio for Antithrombotic/Anticoagulant Drug Treatment
Table 86 : Merck & Co. Inc.: Financial Performance, 2018-2022
Table 87 : Pfizer Inc.: Product Segments
Table 88 : Pfizer Inc.: Key Financials, 2021
Table 89 : Sanofi: Products Portfolio for Antithrombotic/Anticoagulant Drugs Treatment
Table 90 : Sanofi: Business Segments
Table 91 : Sanofi: Financial Performance,2021 and 2022
Table 92 : Sanofi: Key Developments, 2019-2023
Table 93 : Government Regulatory Agencies and Professional Organizations Associated with Cardiac Biomarkers